224 related articles for article (PubMed ID: 12409575)
1. Effect of race on biochemical disease-free outcome in patients with prostate cancer treated with definitive radiation therapy in an equal-access health care system: radiation oncology report of the Department of Defense Center for Prostate Disease Research.
Johnstone PA; Kane CJ; Sun L; Wu H; Moul JW; McLeod DG; Martin DD; Kusuda L; Lance R; Douglas R; Donahue T; Beat MG; Foley J; Baldwin D; Soderdahl D; Do J; Amling CL
Radiology; 2002 Nov; 225(2):420-6. PubMed ID: 12409575
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of race on biochemical control in patients with localized prostate cancer treated with permanent brachytherapy: multivariate and matched-pair analyses.
Lee LN; Barnswell C; Torre T; Fearn P; Kattan M; Potters L
Int J Radiat Oncol Biol Phys; 2002 Jun; 53(2):282-9. PubMed ID: 12023131
[TBL] [Abstract][Full Text] [Related]
3. Impact of biochemical failure on overall survival after radiation therapy for localized prostate cancer in the PSA era.
Kupelian PA; Buchsbaum JC; Patel C; Elshaikh M; Reddy CA; Zippe C; Klein EA
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):704-11. PubMed ID: 11849793
[TBL] [Abstract][Full Text] [Related]
4. Effect of age on biochemical disease-free outcome in patients with T1-T3 prostate cancer treated with definitive radiotherapy in an equal-access health care system: a radiation oncology report of the Department of Defense Center for Prostate Disease Research.
Johnstone PA; Riffenburgh RH; Moul JW; Sun L; Wu H; McLeod DG; Kane CJ; Martin DD; Kusuda L; Lance R; Douglas R; Donahue T; Beat MG; Foley J; Chung A; Soderdahl D; Do J; Amling CL;
Int J Radiat Oncol Biol Phys; 2003 Mar; 55(4):964-9. PubMed ID: 12605974
[TBL] [Abstract][Full Text] [Related]
5. The impact of race on biochemical disease-free survival in early-stage prostate cancer patients treated with surgery or radiation therapy.
Hart KB; Wood DP; Tekyi-Mensah S; Porter AT; Pontes JE; Forman JD
Int J Radiat Oncol Biol Phys; 1999 Dec; 45(5):1235-8. PubMed ID: 10613318
[TBL] [Abstract][Full Text] [Related]
6. Prostate cancer in African-American men: outcome following radiation therapy with or without adjuvant androgen ablation.
Zagars GK; Pollack A; Pettaway CA
Int J Radiat Oncol Biol Phys; 1998 Oct; 42(3):517-23. PubMed ID: 9806509
[TBL] [Abstract][Full Text] [Related]
7. Improvement in relapse-free survival throughout the PSA era in patients with localized prostate cancer treated with definitive radiotherapy: year of treatment an independent predictor of outcome.
Kupelian PA; Buchsbaum JC; Elshaikh MA; Reddy CA; Klein EA
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):629-34. PubMed ID: 14529766
[TBL] [Abstract][Full Text] [Related]
8. Effect of obesity on prostate-specific antigen recurrence after radiation therapy for localized prostate cancer as measured by the 2006 Radiation Therapy Oncology Group-American Society for Therapeutic Radiation and Oncology (RTOG-ASTRO) Phoenix consensus definition.
Stroup SP; Cullen J; Auge BK; L'Esperance JO; Kang SK
Cancer; 2007 Sep; 110(5):1003-9. PubMed ID: 17614338
[TBL] [Abstract][Full Text] [Related]
9. Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland.
Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):664-73. PubMed ID: 11849788
[TBL] [Abstract][Full Text] [Related]
10. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
Kupelian P; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):795-9. PubMed ID: 15925452
[TBL] [Abstract][Full Text] [Related]
11. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995.
Kupelian P; Kuban D; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A
Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):415-9. PubMed ID: 15667961
[TBL] [Abstract][Full Text] [Related]
12. Race and survival of men treated for prostate cancer on radiation therapy oncology group phase III randomized trials.
Roach M; Lu J; Pilepich MV; Asbell SO; Mohiuddin M; Grignon D
J Urol; 2003 Jan; 169(1):245-50. PubMed ID: 12478146
[TBL] [Abstract][Full Text] [Related]
13. Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy.
Lee AK; Levy LB; Cheung R; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):456-62. PubMed ID: 15927415
[TBL] [Abstract][Full Text] [Related]
14. Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men.
Moul JW; Sesterhenn IA; Connelly RR; Douglas T; Srivastava S; Mostofi FK; McLeod DG
JAMA; 1995 Oct; 274(16):1277-81. PubMed ID: 7563532
[TBL] [Abstract][Full Text] [Related]
15. The impact of race on freedom from prostate-specific antigen failure in prostate cancer patients treated with definitive radiation therapy.
Young CD; Lewis P; Weinberg V; Lee TT; Coleman CW; Roach M
Semin Urol Oncol; 2000 May; 18(2):121-6. PubMed ID: 10875452
[TBL] [Abstract][Full Text] [Related]
16. Race is not an independent predictor of biochemical recurrence after radical prostatectomy in an equal access medical center.
Freedland SJ; Jalkut M; Dorey F; Sutter ME; Aronson WJ
Urology; 2000 Jul; 56(1):87-91. PubMed ID: 10869631
[TBL] [Abstract][Full Text] [Related]
17. Presalvage prostate-specific antigen (PSA) and PSA doubling time as predictors of biochemical failure of salvage cryotherapy in patients with locally recurrent prostate cancer after radiotherapy.
Spiess PE; Lee AK; Leibovici D; Wang X; Do KA; Pisters LL
Cancer; 2006 Jul; 107(2):275-80. PubMed ID: 16770783
[TBL] [Abstract][Full Text] [Related]
18. Radiation dose response in patients with favorable localized prostate cancer (Stage T1-T2, biopsy Gleason < or = 6, and pretreatment prostate-specific antigen < or = 10).
Kupelian PA; Buchsbaum JC; Reddy CA; Klein EA
Int J Radiat Oncol Biol Phys; 2001 Jul; 50(3):621-5. PubMed ID: 11395228
[TBL] [Abstract][Full Text] [Related]
19. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
Kupelian PA; Katcher J; Levin HS; Klein EA
Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1043-52. PubMed ID: 9169811
[TBL] [Abstract][Full Text] [Related]
20. A critical analysis of the interpretation of biochemical failure in surgically treated patients using the American Society for Therapeutic Radiation and Oncology criteria.
Gretzer MB; Trock BJ; Han M; Walsh PC
J Urol; 2002 Oct; 168(4 Pt 1):1419-22. PubMed ID: 12352408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]